2 results
Approved WMOCompleted
To investigate if sunitinib has clinical significant activity in patients with metastatic/recurrent paraganglioma/pheochromocytoma.
Approved WMOCompleted
The primary objective of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic NSCLC patients naive to ALK inhibitors, as evidenced by PFS.The secondary objectives of the study are:1. To…